{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octagam+10%25&page=2", "query": { "intervention": "Octagam 10%", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Octagam+10%25&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T02:56:44.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03292861", "title": "The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2018-09-13", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03292861" }, { "nct_id": "NCT03961009", "title": "Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency Disease" ], "interventions": [ { "name": "Kedrion IVIG 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kedrion S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "2 Years to 70 Years" }, "enrollment_count": 47, "start_date": "2019-04-30", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 11, "location_summary": "North Palm Beach, Florida • Chicago, Illinois • Overland Park, Kansas + 7 more", "locations": [ { "city": "North Palm Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Plymouth", "state": "Minnesota" }, { "city": "Little Silver", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03961009" }, { "nct_id": "NCT02240407", "title": "Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pompe Disease" ], "interventions": [ { "name": "Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase", "type": "GENETIC" }, { "name": "Rapamycin", "type": "DRUG" }, { "name": "saline", "type": "OTHER" }, { "name": "Rituxan", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Lidocaine", "type": "DRUG" }, { "name": "LMX 4 Topical Cream", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 2, "start_date": "2017-10-17", "completion_date": "2021-08-26", "has_results": false, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02240407" }, { "nct_id": "NCT01300728", "title": "Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mild Cognitive Impairment" ], "interventions": [ { "name": "NewGam 10% IVIG", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Sutter Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "50 Years to 84 Years" }, "enrollment_count": 52, "start_date": "2011-01-01", "completion_date": "2020-03-12", "has_results": true, "last_update_posted_date": "2022-10-27", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300728" }, { "nct_id": "NCT00606905", "title": "Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Miscarriage, Recurrent", "Abortion, Habitual" ], "interventions": [ { "name": "Gamimune N or Gamunex 10%", "type": "BIOLOGICAL" }, { "name": "normal saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 82, "start_date": "1999-11", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2012-10-08", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606905" }, { "nct_id": "NCT00220779", "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 128, "start_date": "2002-12", "completion_date": "2005-02", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220779" }, { "nct_id": "NCT01524887", "title": "Phase 3 IGIV, 10% in Alzheimer´s Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer´s Disease" ], "interventions": [ { "name": "Immune Globulin Intravenous (Human), 10% Solution", "type": "BIOLOGICAL" }, { "name": "Human albumin 0.25%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 508, "start_date": "2012-01-23", "completion_date": "2013-07-16", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524887" }, { "nct_id": "NCT02788188", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Middle East Respiratory Syndrome Coronavirus" ], "interventions": [ { "name": "SAB-301", "type": "BIOLOGICAL" }, { "name": "Normal (9%) Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 38, "start_date": "2016-05-28", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02788188" }, { "nct_id": "NCT02593188", "title": "Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Primary Immunodeficiency Diseases (PID)" ], "interventions": [ { "name": "HYQVIA", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 264, "start_date": "2015-11-12", "completion_date": "2021-10-21", "has_results": false, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 30, "location_summary": "Bakersfield, California • Irvine, California • Redondo Beach, California + 24 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02593188" }, { "nct_id": "NCT04565015", "title": "Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immune Deficiency" ], "interventions": [ { "name": "GC5107", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GC Biopharma Corp", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "2 Years to 16 Years" }, "enrollment_count": 24, "start_date": "2020-12-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-09-26T02:56:44.312Z", "location_count": 5, "location_summary": "Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Dallas", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04565015" } ] }